高收入国家癌症手术使用的循证基准:一项基于人群的分析
该研究基于高收入国家指南和澳大利亚流行病学数据,构建并验证了30种癌症部位的手术基准率模型。结果显示2014年澳大利亚新诊断癌症患者中58%(95%CI 57-59)至少接受一次手术,不同部位从前列腺癌23%到睾丸癌99%不等。西南悉尼观察率与基准多数可比,但前列腺癌高29%、肺癌低14%。
要点
- 高收入国家癌症手术总体基准率为58%,不同癌种差异大。
- 前列腺癌观察手术率比基准高29%,肺癌低14%。
- 模型可用于规划癌症手术服务和评估治疗差距。
核心结论
- 澳大利亚2014年新诊断癌症患者中58%(95%CI 57-59)至少一次手术,部位间从23%到99%不等。
- 观察率与基准多数可比,但前列腺癌高29%、肺癌低14%,需深入分析差异。
研究设计与样本
- 基于人群的分析,映射30种癌症部位的手术治疗路径并构建基准模型。
- 使用澳大利亚2017年流行病学数据,以2006-12年西南悉尼观察率验证。
主要发现
- 手术基准率从前列腺癌23%(95%CI 17-27)到睾丸癌99%(95%CI 96-99)。
- 西南悉尼多数癌症观察手术率与基准可比。
- 前列腺癌观察率绝对增加29%,肺癌绝对降低14%。
关键数值与推荐
- 手术指征定义为手术为特定临床场景首选治疗。
- 基准率通过临床路径概率相乘相加估计。
临床怎么用
- 模型可为高收入和新兴经济体合理规划与评估癌症手术服务提供模板。
- 观察率与基准差异提示需分析治疗差距和资源分配。
局限性
- 部分癌症 modelled 与观察手术率存在差异,需深入分析。
- 模型基于高收入国家指南和澳大利亚数据,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Estimating a population-level benchmark rate for use of surgery in the management of cancer helps to identify treatment gaps, estimate the survival impact of such gaps, and benchmark the workforce and other resources, including budgets, required to meet service needs. A population-based benchmark for use of surgery in high-income settings to inform policy makers and service provision has not been developed but was recommended by the Lancet Oncology Commission on Global Cancer Surgery. We aimed to develop and validate a cancer surgery benchmarking model. METHODS: We examined the latest clinical guidelines from high-income countries (Australia, the UK, the EU, the USA, and Canada) and mapped surgical treatment pathways for 30 malignant cancer sites (19 individual sites and 11 grouped as other cancers) that were notifiable in Australia in 2014, broadly reflecting contemporary high-income models of care. The optimal use of surgery was considered as an indication for surgery where surgery is the treatment of choice for a given clinical scenario. Population-based epidemiological data, such as cancer stage, tumour characteristics, and fitness for surgery, were derived from Australia and other similar high-income settings for 2017. The probabilities across the clinical pathways of each cancer were multiplied and added together to estimate the population-level benchmark rates of cancer surgery, and further validated with the comparisons of observed rates of cancer surgery in the South Western Sydney Local Health District in 2006-12. Univariable and multivariable sensitivity analyses were done to explore uncertainty around model inputs, with mean (95% CI) benchmark surgery rates estimated on the basis of 10 000 Monte Carlo simulations. FINDINGS: Surgical treatment was indicated in 58% (95% CI 57-59) of newly diagnosed patients with cancer in Australia in 2014 at least once during the course of their treatment, but varied by site from 23% (17-27) for prostate cancer to 99% (96-99) for testicular cancer. Observed cancer surgery rates in South Western Sydney were comparable to the benchmarks for most cancers, but were higher for some cancers, such as prostate (absolute increase of 29%) and lower for others, such as lung (-14%). INTERPRETATION: The model provides a new template for high-income and emerging economies to rationally plan and assess their cancer surgery provision. There are differences in modelled versus observed surgery rates for some cancers, requiring more in-depth analysis of the observed differences. FUNDING: University of New South Wales Scientia Scholarship, UK Research and Innovation-Global Challenges Research Fund.
引用
- Perera SK, Jacob S, Sullivan R, et al. Evidence-based benchmarks for use of cancer surgery in high-income countries: a population-based analysis. Lancet Oncol. 2021. PMID: 33485459. doi:10.1016/S1470-2045(20)30589-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。